Compare · AVR vs EW
AVR vs EW
Side-by-side comparison of Anteris Technologies Global Corp. (AVR) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVR and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $48.42B, about 78.3x AVR ($618.4M).
- Over the past year, AVR is up 56.7% and EW is up 11.8% - AVR leads by 44.8 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- EW has more recent analyst coverage (25 ratings vs 6 for AVR).
- Company
- Anteris Technologies Global Corp.
- Edwards Lifesciences Corporation
- Price
- $6.36+3.33%
- $83.99+0.54%
- Market cap
- $618.4M
- $48.42B
- 1M return
- +19.55%
- +3.30%
- 1Y return
- +56.65%
- +11.80%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 5
- Recent ratings
- 6
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AVR
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- SEC Form EFFECT filed by Anteris Technologies Global Corp.
- Cantor Fitzgerald resumed coverage on Anteris Technologies Global Corp. with a new price target
- Wells Fargo initiated coverage on Anteris Technologies Global Corp. with a new price target
- SEC Form POS AM filed by Anteris Technologies Global Corp.
Latest EW
- Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits